Helicobacter Pylori Serology Testing

Table of Contents

Coverage Policy .................................................. 1
Overview.............................................................. 1
General Background ........................................... 1
Coding/Billing Information ................................... 3
References .......................................................... 4

Related Coverage Resources

Pharmacogenetic Testing

INSTRUCTIONS FOR USE

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer’s benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer’s benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

Coverage Policy

Serology/antibody testing (CPT code 86677) for diagnosing Helicobacter pylori infection or ANY other indication is considered experimental, investigational, and unproven.

Overview

This Coverage Policy addresses serology testing for Helicobacter pylori infection which is associated with peptic ulcer disease.

General Background

Helicobacter pylori (H. pylori) is a key causal factor in most peptic ulcer disease and a primary risk factor for gastric cancer. The pathogenic role of H. pylori in peptic ulcer disease, both duodenal and gastric, is well-recognized. Nearly 95% of patients with duodenal ulcers and 80% of patients with gastric ulcers are found to be infected with H. pylori. Treatment for H. pylori infection includes varied combinations of antibiotics, proton pump inhibitors (PPIs), histamine H2 receptor antagonists and bismuth compounds. Eradication of H. pylori significantly lowers the recurrence rate of H. pylori-associated peptic ulcers.

H. Pylori Testing Methods
H. pylori infection can be confirmed by invasive or noninvasive methods. Invasive tests require upper esophagogastroduodenal (EGD) endoscopy, which is considered the reference method of diagnosis. During endoscopy, biopsy specimens of the stomach and duodenum are obtained, and the diagnosis of H. pylori can be made by urease testing, histology and/or culture. If possible, noninvasive testing is done before tissue testing. Noninvasive methods include stool antigen testing (e.g. H. pylori stool antigen [HpSA]), serology, and urea breath testing (UBT). The clinical utility of these testing methods lies in their ability to accurately identify H. pylori infection, which allows for subsequent treatment and eradication. The UBT has been proven to be a safe and effective test for identifying the presence of H. pylori with a reported sensitivity of 94.7% and specificity 95.7% (Vakil, 2005). The accuracy of the UBT is comparable to endoscopic biopsy (Islam, et al., 2005; Perri, et al., 2005). Sensitivity and specificity ranges of 90%-93% and 91%-100% respectively, have been reported for stool antigen testing (Canadian Agency for Drugs and Technologies in Health [CADTH], 2015).

Serological assays measure specific H. pylori immunoglobulin G (IgG) antibodies that can determine if an individual has been infected. Serological testing has been the mainstay of H. pylori diagnosis, particularly in primary care, due to the accessibility, rapid results and low cost of this testing method. However, some serological tests have not been locally validated and therefore have suboptimal sensitivity and specificity in practice. The value of noninvasive H. pylori testing is also related to the background prevalence of H. pylori infection. False-positives are more likely to occur in areas where H. pylori infections are less prevalent (Talley, et al., 2005a). Serological tests are also unreliable indicators of H. pylori status in patients who have received treatment for the infection. Because it cannot distinguish between current and past infection, serological testing has poor accuracy in settings of low and intermediate H. pylori prevalence, limiting its value in the United States (Vakil and Fendrick, 2005).

Serology testing for H. pylori pre-dates the UBT and the stool antigen testing, and has been reported to have decreased accuracy based on local validation with a wider sensitivity and specificity range of 80–95%. Since the positive predictive value of antibody testing is influenced by the prevalence of an infection, the PPV in areas of low prevalence such as much of the United States is poor. A positive test has little value in predicting the actual presence of an active infection. False-positives lead to inappropriate treatment, as well as lack of treatment response and encouragement of antibiotic resistance (Vakil and Fendrick, 2005). The low accuracy of serology testing results in the need for additional confirmatory non-invasive (i.e., UBT, stool antigen), or invasive (i.e., endoscopy/biopsy) testing. Therefore the performance and clinical utility of this testing method compared to other non-invasive methods is lacking.

Professional Societies/Organizations
According to the American College of Gastroenterology (ACG) practice guidelines for the management of H. pylori infection, antibody testing (e.g., serum, whole blood, urine) is widely available but has poor positive predictive value in populations with a low prevalence of H. pylori infection, limiting its usefulness in clinical practice. Antibody testing is of limited benefit in documenting eradication of H. pylori, as results can remain positive years after successful cure of the infection (Chey, et al., 2007). Testing to prove H. pylori eradication should be performed using a urea breath test, fecal antigen test or biopsy-based testing at least four weeks after the completion of antibiotic therapy and one–two weeks after PPI therapy has been withheld. The ACG notes that “because of the higher pretest probability of infection, patients with documented PUD represent a rare group, where it is acceptable to utilize an IgG H. pylori antibody test.” In most other scenarios in which the pretest probability of infection is lower, tests which identify active disease are preferred over antibody testing (Chey, et al., 2017).

The 2016 recommendation from the American Society for Clinical Pathology states “Serologic evaluation of patients to determine the presence/absence of Helicobacter pylori (H. pylori) infection is no longer considered clinically useful. Alternative noninvasive testing methods (e.g., the urea breath test and stool antigen test) exist for detecting the presence of the bacteria and have demonstrated higher clinical utility, sensitivity, and specificity” (American Board of Internal Medicine’s (ABIM) Foundation Choosing Wisely® Initiative [2017]).

The American Gastroenterological Association (AGA) medical position statement on the evaluation of dyspepsia states that noninvasive H. pylori testing is optimally performed by a 13C-urea breath test or stool antigen test (Talley, 2005b).
Use Outside of the US

Italian guidelines published by Zagaria et al (2015) state that the H. Pylori test-and-treat strategy is appropriate for the initial management of uninvestigated dyspepsia as H. Pylori prevalence in adults in Italy is over 20%. This approach is applicable to patients younger than 50 years without alarm symptoms. All dyspeptic patients older than 50 years or with alarm signs or symptoms should be referred for upper endoscopy. The guidelines further state that when the test-and-treat strategy is applied, an accurate diagnosis is mandatory using a non-invasive test, either the $^{13}$C-urea breath test (UBT) or the monoclonal stool antigen test (SAT). These testing methods have shown high diagnostic accuracy in both the pre- and post-HP treatment setting (Zagaria, et al., 2015).

The European Helicobacter Study Group (EHSG) promotes multidisciplinary research and organizes consensus conferences to explore issues surrounding H. pylori infection. The Fourth Maastricht/Florence Consensus Conference included 44 experts from 24 countries who issued the following recommendations regarding diagnostic testing for H. pylori (Malfertheiner, et al., 2012):

1. The diagnostic accuracy of the stool antigen test (SAT) is equivalent to the UBT if a validated laboratory-based monoclonal test is used.
2. The serological tests are not all equivalent. Only validated IgG serology tests should be used owing to variability in the accuracy of different commercial tests. Evidence level: 1b; Grade of recommendation: B
3. In patients treated with PPIs: if possible, PPI should be stopped for two weeks before testing by culture, histology, rapid urease test, UBT or stool test. Evidence level: 1b; Grade of recommendation: A
4. If it is not possible, validated IgG serology can be performed. Evidence level: 2b; Grade of recommendation:

Joint evidence-based guidelines from the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN), and the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) include the following regarding H. pylori testing methods (Koletzko, et al., 2011):

1. It is recommended that the initial diagnosis of H. pylori infection be based on a positive histopathology plus a positive rapid urease test or a positive culture.
2. The $^{13}$C-urea breath test (UBT) is a reliable noninvasive test to determine whether H. pylori has been eradicated.
3. A validated enzyme-linked immunosorbent assay (ELISA) test for detection of H pylori antigen in stool is a reliable noninvasive test to determine whether H pylori has been eradicated.
4. Tests based on the detection of antibodies (IgG, IgA) against H. pylori in serum, whole blood, urine, and saliva are not reliable for use in the clinical setting.
5. It is recommended that clinicians wait at least 2 weeks after stopping proton pump inhibitor (PPI) therapy and 4 weeks after stopping antibiotics to perform biopsy-based and noninvasive tests (UBT, stool test) for H pylori.

The National Institute for Health and Care Excellence (NICE) guidelines for the management of gastroesophageal reflux disease and dyspepsia in adults state that H. pylori can be initially detected using either a carbon-13 urea breath test (UBT), stool antigen test or laboratory-based serology where its performance has been locally validated. Re-testing for H pylori should be performed using a carbon-13 UBT, as there is currently insufficient evidence to recommend the stool antigen test as a test of eradication. NICE does not recommend the use office-based serological tests for H pylori because of inadequate performance (NICE, 2014).

Coding/Billing Information

Note: 1) This list of codes may not be all-inclusive.
2) Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement.
Considered Experimental/Investigational/Unproven:

<table>
<thead>
<tr>
<th>CPT* Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>86677</td>
<td>Antibody; Helicobacter pylori</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ICD-9-CM Diagnosis Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>All codes</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ICD-10-CM Diagnosis Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>All codes</td>
<td></td>
</tr>
</tbody>
</table>


References


